Omni Peptides
ARA-290
Couldn't load pickup availability
ARA-290 (also known as Cibinetide or PH-BSP) is a synthetic 11-amino-acid peptide derived from the helix B surface domain of erythropoietin (EPO). This research compound is engineered to selectively activate the innate repair receptor (IRR, a heteromer of EPOR and β-common receptor/CD131) while lacking hematopoietic (red blood cell-stimulating) activity. It has attracted significant scientific interest for its potent tissue-protective, anti-inflammatory, and neuroprotective effects. Preliminary and advanced preclinical studies indicate that ARA-290 may reduce inflammation, promote tissue repair, alleviate neuropathic pain, protect against ischemia-reperfusion injury, and improve metabolic and microvascular function. Researchers utilize ARA-290 in laboratory and animal models to investigate mechanisms of non-hematopoietic EPO signaling, cytoprotection, chronic inflammation, neuropathy, and regenerative medicine. As a research-grade compound, ARA-290 is intended exclusively for in vitro and animal studies. Scientists value its high selectivity, short sequence, and ability to mimic EPO’s tissue-protective benefits without erythropoietic side effects.
Research Applications
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.
— About this compound
ARA-290 is a synthetic erythropoietin-derived peptide.
ARA-290 (also known as Cibinetide or PH-BSP) is a synthetic 11-amino-acid peptide derived from the helix B surface domain of erythropoietin (EPO). This research compound is engineered to selectively activate the innate repair receptor (IRR, a heteromer of EPOR and β-common receptor/CD131) while lacking hematopoietic (red blood cell-stimulating) activity. It has attracted significant scientific interest for its potent tissue-protective, anti-inflammatory, and neuroprotective effects. Preliminary and advanced preclinical studies indicate that ARA-290 may reduce inflammation, promote tissue repair, alleviate neuropathic pain, protect against ischemia-reperfusion injury, and improve metabolic and microvascular function. Researchers utilize ARA-290 in laboratory and animal models to investigate mechanisms of non-hematopoietic EPO signaling, cytoprotection, chronic inflammation, neuropathy, and regenerative medicine. As a research-grade compound, ARA-290 is intended exclusively for in vitro and animal studies. Scientists value its high selectivity, short sequence, and ability to mimic EPO’s tissue-protective benefits without erythropoietic side effects.
Research Applications
Where researchers apply it.
— Verified & Documented
Every vial is backed by a Certificate of Analysis.
Each lot is independently characterised by HPLC and mass spectrometry, with identity, mass and purity documented per batch and available on request.
Additional quality-control testing, including sterility, endotoxin and heavy metals, is conducted periodically across our product range.
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.